These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 16650917

  • 1. Induction of protective and mucosal immunity against diphtheria by a immune stimulating complex (ISCOMS) based vaccine.
    Aguila A, Donachie AM, Peyre M, McSharry CP, Sesardic D, Mowat AM.
    Vaccine; 2006 Jun 12; 24(24):5201-10. PubMed ID: 16650917
    [Abstract] [Full Text] [Related]

  • 2. The mucosal adjuvanticity of the oligodeoxynucleotides containing a non-methylated CpG motif on BCG and diphtheria toxoid.
    Maeyama J, Komiya T, Takahashi M, Isaka M, Goto N, Yamamoto S.
    Vaccine; 2009 Feb 18; 27(8):1166-73. PubMed ID: 19136040
    [Abstract] [Full Text] [Related]

  • 3. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
    Olive C, Sun HK, Ho MF, Dyer J, Horváth A, Toth I, Good MF.
    J Infect Dis; 2006 Aug 01; 194(3):316-24. PubMed ID: 16826479
    [Abstract] [Full Text] [Related]

  • 4. The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis.
    Andersen CS, Dietrich J, Agger EM, Lycke NY, Lövgren K, Andersen P.
    Infect Immun; 2007 Jan 01; 75(1):408-16. PubMed ID: 17074845
    [Abstract] [Full Text] [Related]

  • 5. Current status and potential application of ISCOMs in veterinary medicine.
    Morein B, Hu KF, Abusugra I.
    Adv Drug Deliv Rev; 2004 Jun 23; 56(10):1367-82. PubMed ID: 15191787
    [Abstract] [Full Text] [Related]

  • 6. A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery.
    McNeela EA, O'Connor D, Jabbal-Gill I, Illum L, Davis SS, Pizza M, Peppoloni S, Rappuoli R, Mills KH.
    Vaccine; 2000 Dec 08; 19(9-10):1188-98. PubMed ID: 11137256
    [Abstract] [Full Text] [Related]

  • 7. Transcutaneous immunization with a novel lipid-based adjuvant protects against Chlamydia genital and respiratory infections.
    Hickey DK, Aldwell FE, Beagley KW.
    Vaccine; 2009 Oct 19; 27(44):6217-25. PubMed ID: 19698810
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of ISCOM vaccines for mucosal immunization against hepatitis B.
    Pandey RS, Dixit VK.
    J Drug Target; 2010 May 19; 18(4):282-91. PubMed ID: 19958131
    [Abstract] [Full Text] [Related]

  • 9. Intranasal vaccination with SfbI or M protein-derived peptides conjugated to diphtheria toxoid confers protective immunity against a lethal challenge with Streptococcus pyogenes.
    Schulze K, Olive C, Ebensen T, Guzmán CA.
    Vaccine; 2006 Aug 28; 24(35-36):6088-95. PubMed ID: 16828529
    [Abstract] [Full Text] [Related]

  • 10. Immune-stimulating complexes induce an IL-12-dependent cascade of innate immune responses.
    Smith RE, Donachie AM, Grdic D, Lycke N, Mowat AM.
    J Immunol; 1999 May 01; 162(9):5536-46. PubMed ID: 10228035
    [Abstract] [Full Text] [Related]

  • 11. CTA1-DD-immune stimulating complexes: a novel, rationally designed combined mucosal vaccine adjuvant effective with nanogram doses of antigen.
    Mowat AM, Donachie AM, Jägewall S, Schön K, Löwenadler B, Dalsgaard K, Kaastrup P, Lycke N.
    J Immunol; 2001 Sep 15; 167(6):3398-405. PubMed ID: 11544331
    [Abstract] [Full Text] [Related]

  • 12. Immune-stimulating complexes containing Quil A and protein antigen prime class I MHC-restricted T lymphocytes in vivo and are immunogenic by the oral route.
    Mowat AM, Donachie AM, Reid G, Jarrett O.
    Immunology; 1991 Mar 15; 72(3):317-22. PubMed ID: 2026440
    [Abstract] [Full Text] [Related]

  • 13. Protection afforded against aerosol challenge by systemic immunisation with inactivated Francisella tularensis live vaccine strain (LVS).
    Eyles JE, Hartley MG, Laws TR, Oyston PC, Griffin KF, Titball RW.
    Microb Pathog; 2008 Feb 15; 44(2):164-8. PubMed ID: 17904793
    [Abstract] [Full Text] [Related]

  • 14. Mucosal immunization with recombinant heparin-binding haemagglutinin adhesin suppresses extrapulmonary dissemination of Mycobacterium bovis bacillus Calmette-Guérin (BCG) in infected mice.
    Kohama H, Umemura M, Okamoto Y, Yahagi A, Goga H, Harakuni T, Matsuzaki G, Arakawa T.
    Vaccine; 2008 Feb 13; 26(7):924-32. PubMed ID: 18192091
    [Abstract] [Full Text] [Related]

  • 15. Induction of systemic and mucosal antibody responses in mice immunized intranasally with aluminium-non-adsorbed diphtheria toxoid together with recombinant cholera toxin B subunit as an adjuvant.
    Isaka M, Yasuda Y, Kozuka S, Taniguchi T, Matano K, Maeyama J, Komiya T, Ohkuma K, Goto N, Tochikubo K.
    Vaccine; 1999 Nov 12; 18(7-8):743-51. PubMed ID: 10547435
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of ISCOMATRIX and ISCOM vaccines for immunisation against Helicobacter pylori.
    Skene CD, Doidge C, Sutton P.
    Vaccine; 2008 Jul 23; 26(31):3880-4. PubMed ID: 18547687
    [Abstract] [Full Text] [Related]

  • 17. Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan.
    McNeela EA, Jabbal-Gill I, Illum L, Pizza M, Rappuoli R, Podda A, Lewis DJ, Mills KH.
    Vaccine; 2004 Feb 25; 22(8):909-14. PubMed ID: 15161067
    [Abstract] [Full Text] [Related]

  • 18. Novel ISCOMs from Quillaja brasiliensis saponins induce mucosal and systemic antibody production, T-cell responses and improved antigen uptake.
    Cibulski SP, Mourglia-Ettlin G, Teixeira TF, Quirici L, Roehe PM, Ferreira F, Silveira F.
    Vaccine; 2016 Feb 24; 34(9):1162-71. PubMed ID: 26826546
    [Abstract] [Full Text] [Related]

  • 19. Oral vaccination against diphtheria using polyacryl starch microparticles as adjuvant.
    Rydell N, Sjöholm I.
    Vaccine; 2004 Mar 12; 22(9-10):1265-74. PubMed ID: 15003656
    [Abstract] [Full Text] [Related]

  • 20. From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1-DD/ISCOM.
    Lycke N.
    Cell Microbiol; 2004 Jan 12; 6(1):23-32. PubMed ID: 14678328
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.